Author: Dr Anika Schröter
The development of RNA-based drugs has increased within the past years and is a promising field of research in the pharmaceutical industry. It is transforming the industry and will offer new hope for patients with unmet medical needs.
RNA-based drugs have several advantages over conventional drugs, such as the ability to target previously undruggable pathways, the rapid and cost-effective development, and the potential for personalized medicine. However, RNA-based drugs also face some challenges, such as the stability, delivery, and safety of the RNA molecules.
This whitepaper informs about the challenges with the 'standard' non-clinical program for different RNA-based drugs, focusing on safety evaluation.
Download now the white paper 'Non-clinical aspects of RNA-based drug development'.
We hope you enjoy reading it!
Stay informed with updates from our global and local experts, who will provide the latest regulatory and legislative insights every two months. In 2026, topics will include CMC documentation, regulatory intelligence, regulatory pathways in Africa, enrichment of PMS product data, global regulatory reliance models and ePI.
This online course shall provide a sound overview about different local laws in important countries in EU and beyond with respect to employee invention rights. It shall enable the participants to address complex situations when designing and negotiating agreements for cross-border R&D.
This online webcast series provides a concise update on the EU Pharmaceutical Package. Across five two-hour modules, you learn about key regulatory changes, revised authorisation and protection rules, new obligations for managing shortages, and developments in environmental risk assessment. Gain practical guidance to adapt internal processes and responsibilities to the upcoming framework.
The course provides practical methods for building and upgrading IP workflows, including competitor analysis, KPI reporting, portfolio scoring, budgeting, and risk assessment. It targets IP managers and patent professionals with prior IP knowledge, offering structured foundations and AI enhanced workflow design.
The online course covers IP management in collaborative research. Topics include models, governance, contractual frameworks, funder obligations, handling of background and foreground IP, software and AI aspects, and typical risks. Workshops with templates and negotiation simulations enable practical application. Target group: professionals with IP knowledge.
Quality & GMP Essentials for Regulatory Affairs/CMC: Managing the interface - knowledge of quality-relevant facts, GMP fundamentals, as well as understanding of the processes at the interface - including an Update on various guideline revisions, e.g. ICH Q1, M4Q(R2) and more - Qualify now!
Compact overview of EU requirements for labelling, UDI and product information under the MDR. Learn how legal obligations translate into practical workflows, including UDI allocation and EUDAMED device registration. Ideal for RA, QA and labelling professionals.
Regulatory expectations regarding risk management for pharmaceuticals in (emerging) markets often contend with the stringent standards set by the EU/ICH regions. Join us in five consecutive webcasts to gain insights into local pharmacovigilance systems in different countries and regions, and learn how to integrate them into your global PV system while maintaining a clear overview!
Join our interactive course to explore how AI is transforming pharmacovigilance. Take part in discussions, hands-on workshops, and case studies while diving into AI technologies, regulations, and their applications in drug safety. Register now to participate, share insights, and collaborate with peers!
The seminar covers essential topics such as stakeholder identification, effective meeting preparation, and legally compliant collaboration. Tailored for Medical Science Liaisons (MSLs) and Medical Affairs teams, the seminar equips you to gain real insights from KOLs, overcome challenging situations, and elevate patient outcomes.
The event will cover recent updates and practical implications of the EU pharmaceutical legislation, the application of AI in RA, and the new EU Variation regulation. Additionally, it will address the latest developments in quality (draft) guidelines: ICH M13A + M13B, ICH M4Q(R2), an update on the ongoing discussions on nitrosamine contaminations, and the revision of PACMP, Lifecycle Management.
